Riboflavin for Migraine Prophylaxis in Children
A retrospective study was conducted on 42 children (aged 6-18 years; mean, 13.8 years) with migraine (at least 4 headache days per month) who were treated with riboflavin at Dell Children’s Medical Center in Austin, Texas. The dosage was 100 mg twice a day for body weight of 20-40 kg, and 200 mg twice a day for greater than 40 kg. Children were evaluated at two and four months, because the efficacy of riboflavin typically begins after one month and stabilizes after three months. The primary outcome measure was the proportion of patients with at least a 50% reduction in headache days from baseline to four months. Twenty-six children (61.9%) had at least a 50% reduction in headache days, five (11.9%) had moderate benefit (30-50% reduction), two (4.8%) had mild benefit (10-30% reduction), and nine (21.4%) had no benefit. In the group as a whole, the mean number of headache days per month decreased by 49% (from 21.9 to 11.1; p < 0.001), mean headache intensity decreased by 74% (p < 0.001), and mean duration of headaches decreased by 44% (p < 0.001). Some patients reported that acute medications that had previously been ineffective became effective.
0 Comments